GB2558442B - Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods - Google Patents

Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods

Info

Publication number
GB2558442B
GB2558442B GB1804143.4A GB201804143A GB2558442B GB 2558442 B GB2558442 B GB 2558442B GB 201804143 A GB201804143 A GB 201804143A GB 2558442 B GB2558442 B GB 2558442B
Authority
GB
United Kingdom
Prior art keywords
antibodies
diagnostic methods
conditions related
treating conditions
associated diagnostic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
GB1804143.4A
Other versions
GB2558442A (en
GB201804143D0 (en
Inventor
Clube Jasper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kymab Ltd
Original Assignee
Kymab Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kymab Ltd filed Critical Kymab Ltd
Priority to GB1804143.4A priority Critical patent/GB2558442B/en
Publication of GB201804143D0 publication Critical patent/GB201804143D0/en
Publication of GB2558442A publication Critical patent/GB2558442A/en
Application granted granted Critical
Publication of GB2558442B publication Critical patent/GB2558442B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
GB1804143.4A 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods Active GB2558442B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
GB1804143.4A GB2558442B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB1804143.4A GB2558442B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
GB1322253.4A GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods

Publications (3)

Publication Number Publication Date
GB201804143D0 GB201804143D0 (en) 2018-05-02
GB2558442A GB2558442A (en) 2018-07-11
GB2558442B true GB2558442B (en) 2018-10-24

Family

ID=50031010

Family Applications (2)

Application Number Title Priority Date Filing Date
GB1804143.4A Active GB2558442B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
GB1322253.4A Active GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods

Family Applications After (1)

Application Number Title Priority Date Filing Date
GB1322253.4A Active GB2521356B (en) 2013-12-17 2013-12-17 Antibodies for use in treating conditions related to specific PCKS9 variants and associated diagnostic methods

Country Status (1)

Country Link
GB (2) GB2558442B (en)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9
EP2671946A1 (en) * 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004097047A1 (en) * 2003-04-25 2004-11-11 Institut National de la Santé et de la Recherche Médicale Mutations in the human pcsk9 gene associated to hypercholesterolemia
EP2671946A1 (en) * 2006-06-30 2013-12-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
WO2009026558A1 (en) * 2007-08-23 2009-02-26 Amgen Inc. Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9)
WO2012054438A1 (en) * 2010-10-22 2012-04-26 Schering Corporation Anti-pcsk9
WO2012088313A1 (en) * 2010-12-22 2012-06-28 Genentech, Inc. Anti-pcsk9 antibodies and methods of use
WO2013091103A1 (en) * 2011-12-20 2013-06-27 Adaerata, Limited Partnership Single domain antibodies as inhibitors of pcsk9

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Clinical Science, Vol 113, 2007, M Scartezini et al, "The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy UK men", 435-441 *
Journal of the American College of Cardiology, Vol 45, 2005, SN Chen et al, "A common PCSK9 haplotype, encompassing the E670G coding single nucleotide polymorphism, is a novel genetic marker...", 1611-1619 *
Lipids in Health and Disease, Vol 12, 2013, J Mayne et al, "Differential effects of PCSK9 loss of function variants on serum lipid and PCSK9 levels in Caucasian and African Canadian populations", 70 *

Also Published As

Publication number Publication date
GB2558442A (en) 2018-07-11
GB201804143D0 (en) 2018-05-02
GB2521356B (en) 2018-10-10
GB201322253D0 (en) 2014-01-29
GB2521356A (en) 2015-06-24

Similar Documents

Publication Publication Date Title
IL282219B (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects
HK1222530A1 (en) Microclosures and related methods for skin treatment
IL244495A0 (en) Anti-alpha-synuclein antibodies and methods of use
HK1221422A1 (en) Diagnostic methods and compositions for treatment of glioblastoma
PL3004833T3 (en) Improvements in and relating to tissue sampling
HK1197187A1 (en) Anti-lrp5 antibodies and methods of use lrp5
HK1225612A1 (en) Anti-ly6e antibodies and methods of use
GB2516343B (en) Improvements in and relating to ophthalmoscopes
GB201305822D0 (en) Improvements in and relating to apparatus and methods
GB2509710B (en) Photobioreactor and its use in waste water treatment
HK1222562A1 (en) Compositions and methods for use in medical diagnosis
SG10201706205RA (en) Methods for reducing aggregate levels in protein preparations by treatment with thio-heterocyclic cations
EP2972796A4 (en) Methods and apparatus to manage concurrent predicate expressions
SG11201600013WA (en) Systems and methods for in vivo irradiation of blood
EP2965091A4 (en) Assay and method for identifying compounds to treat tauopathies
GB2522177B (en) Improvements in and relating to sampling
GB2558442B (en) Antibodies for use in treating conditions related to specific PCSK9 variants and associated diagnostic methods
GB201318468D0 (en) Improvements in and relating to processing methods and processing apparatus
IL244576A0 (en) Anti-vstm5 antibodies and the use thereof in therapy and diagnosis
GB201302884D0 (en) Novel methods for diagnosis and therapy
GB201300540D0 (en) Improvements in and relating to stimulating needles
GB201304148D0 (en) Improvements in or relating to treatment apparatus
PT3395836T (en) Human antibodies to pcsk9 for use in methods of treating particular groups of subjects